Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Financing Activities (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Cash from Financing Activities for 5 consecutive years, with $15.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 545.22% to $15.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, down 67.78% year-over-year, with the annual reading at $8.7 million for FY2025, 67.78% down from the prior year.
  • Cash from Financing Activities hit $15.7 million in Q4 2025 for Krystal Biotech, up from $3.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $202.1 million in Q4 2021 to a low of -$12.5 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $31.1 million across 5 years, with a median of $3.2 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: soared 15527.14% in 2022 and later tumbled 217.79% in 2025.
  • Year by year, Cash from Financing Activities stood at $202.1 million in 2021, then plummeted by 98.48% to $3.1 million in 2022, then fell by 14.66% to $2.6 million in 2023, then fell by 7.29% to $2.4 million in 2024, then skyrocketed by 545.22% to $15.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for KRYS at $15.7 million in Q4 2025, $3.7 million in Q3 2025, and $1.8 million in Q2 2025.